ZBH — Zimmer Biomet Holdings, Inc.

Is ZBH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Zimmer Biomet Holdings, Inc. (ZBH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $102.09. The rating moved from Neutral to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Zimmer Biomet is positioned to benefit from steady elective orthopedics demand and an installed-base-driven aftermarket business that supports cash generation. Growth catalysts include broader adoption of surgical robotics and ongoing product cycle refreshes, while margin expansion depends on successful cost actions and commercialization execution. Near-term performance will remain sensitive to macro-driven procedure volumes, competitive dynamics in robotics and potential regulatory or product-liability events.

Key factors

  • Leading position in orthopedics with sizeable recurring aftermarket and instrument revenue supporting margin stability
  • Demographic tailwind from aging populations driving steady elective joint-replacement demand over medium term
  • Opportunity from surgical-robotics expansion and system/consumable sales that can increase ASPs and recurring revenue
  • Ongoing product portfolio refresh and targeted cost initiatives that can improve operating margins and free cash flow
  • Relatively diversified end-markets (orthopedics, spine, dental, sports medicine) reducing single-segment exposure
  • Solid commercial footprint and installed base that supports cross-sell and service revenue resilience

Risks

  • Cyclicality of elective procedures: macro weakness, reimbursement changes, or pandemic-like disruptions can compress volumes
  • Competitive pressure and pricing dynamics from larger medtech players and new surgical-robotics entrants, pressuring market share
  • Regulatory, recall, or product-liability events that could trigger remediation costs and reputational damage
  • Execution risk on robotics and new-product rollouts; slower-than-expected adoption would delay revenue uplift
  • Supply-chain or manufacturing disruptions that could increase costs or cause product shortages
  • Potential M&A integration challenges or increased leverage if the company pursues sizable acquisitions

See today's live rating, score and targets

Members see the live hourly rating for ZBH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.